CND Life Sciences, a biotechnology firm revolutionizing neurodegenerative disease diagnostics, has successfully raised $13.5 million in its Series A funding round, including $8.6 million from its recent Series A3 tranche. This funding milestone will further accelerate the adoption of CND’s flagship innovation—the Syn-One Test®, a skin biopsy-based diagnostic tool designed to detect abnormal alpha-synuclein, a protein closely associated with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy, and related disorders.
“This is a transformative period for the neurodegeneration field,” said Richard J. Morello, CEO of CND Life Sciences. “Our platform is enhancing early and accurate diagnosis while supporting pharmaceutical research aimed at delivering groundbreaking therapies. We’re deeply thankful for the continued backing from our investor community.”
Syn-One Test®: A Game-Changer in Neurological Diagnosis
Launched in late 2019, the Syn-One Test has been adopted by nearly 3,000 clinicians, helping diagnose over 35,000 patients with synuclein-associated disorders. A landmark 2024 study published in the Journal of the American Medical Association (JAMA) validated the test’s effectiveness, reporting a 95.5% sensitivity in detecting abnormal alpha-synuclein levels in patients with various neurodegenerative conditions.
CND’s AI-powered platform, NerValence™, supports Syn-One Biomarker Technology™, enabling the quantification of synuclein in cutaneous nerves. This data-driven insight is being integrated into pharmaceutical clinical trials, aiding researchers in evaluating the impact of investigational treatments on neurodegenerative disease markers.
Supporting Drug Development and Improved Patient Outcomes
“Accurate diagnosis and objective measurement of disease progression are critical for the success of new therapies,” stated Dr. Christopher Gibbons, Chief Scientific Officer at CND. “Our proprietary solutions deliver both diagnostic precision and measurable disease tracking, paving the way for improved patient care and faster development of disease-modifying treatments.”
Strategic Investment and Partnerships
The Series A3 round saw participation from both new and returning investors, including Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, and BlueStone Ventures. Notably, Labcorp, a global leader in lab services, joined the round alongside MBX Capital and Vilas Ventures.
“We are proud to support CND Life Sciences as they scale access to the Syn-One Test,” said Megann Vaughn Watters, Vice President of New Ventures & Strategic Alliances at Labcorp. “The strong adoption among clinicians and the actionable insights provided by this innovation align with our mission to close care gaps and improve outcomes for patients with neurodegenerative conditions.”
Looking Ahead
With this latest round of funding, CND Life Sciences is poised to expand its impact on the neurology and diagnostics landscape. By bridging clinical needs with technological innovation, the company aims to lead the global effort in enhancing early detection and personalized treatment strategies for Parkinson’s disease and related disorders.